Enteric Microencapsulate capsule
Aspirin, the active ingredient of Casprin E.M. Capsules, is the most widely
used drug in the world for pain relief. More recently, it has been used as
an antiplatelet agent to prevent thrombosis and embolism, and has been
formulated as an enteric coated low-dose preparation for the prophylaxis and
treatment of transient ischemic attacks (TIA) and other thromboembolic
Each vegetable capsule contains:
Pharmacology (Summary of Pharmacodynamics and Pharmacokinetics)
1. Aspirin is an analgesics, anti-inflammatory, antipyretic and an inhibitor
of platelet aggregation. It acetylates the enzymes cyclo-oxygenase thereby
inhibiting the synthesis of prostaglandins, thromboxane in the circulation
platelets, and prostacyclin in the systemic vascular endothelium.
Thromboxane is a vasoconstrictor and it induces platelet aggregation, while
prostacyclin is a vasodilator and inhibitor of platelet aggregation.
2. The antiplatelet aggregating effect of Casprin is postulated to retard or
reduce the development of thromboembolic disorders. The low dose, enteric
coated, and relatively slow rate of release of Aspirin is observed to
selectively and irreversibly inhibit thromboembolic synthesis. Aspirin
inhibits thromboxane synthesis in the portal circulation and is
presystemically metabolised to salicylate with negligible amount reaching
the systemic circulation to inhibit prostacyclin synthesis. Salicylate is
effectively inactive at the blood concentrations achieved clinically and
prostacyclin is less sensitive than thromboxane to Aspirin.
3. In order to eliminate the gastrointestinal adverse effects of Aspirin, an
enteric coated low-dose Aspirin (as pellets) was developed by Yung Shin
Pharmaceutics. The advantages of enteric-microencapsulated capsules include
ready distribution over a large area, thus minimizing the risk of local
damage caused by the dumping effect of enteric coated tablets. Furthermore,
Casprin Enteric-Microencapsulated Capsules are also less dependent on
gastric transient time. They may attain more constant plasma level, achieve
slow-release effect, give higher accuracy in reproducibility between doses,
and provide less decreases in bioavailability.
4. Following oral administration, absorption of Aspirin occurs in the
intestine. Some Aspirin is hydrolysed to salicylate in the gut wall. Aspirin
is bound to plasma protein and is widely distributed. Plasma Aspirin
concentrations decline rapidly (half life 15 to 20 minutes) as plasma
salicylates concentrations increases.
5. Aspirin is rapidly converted by esterases present in plasma and many
tissues, especially the liver, to salicylic acid which itself has some
antipyretic, analgesic and anti-inflammatory actions, but which has little
effects on platelets. Salicylic acid is metabolised in the liver to the
glycine conjugate salicyluric acid. Other metabolites include salicyl
phenolic glucuronide, salicyl acyl glucuronide and gentisic acid. Excretion
of salicylic acid in urine is pH dependent; approximately 80% appears
unchanged in urine at pH 8, but only around 10% at pH 4.
6. Since enteric coated pellets of Aspirin can reduce gastrointestinal side
effects that may occur with conventional or other enteric coated tablet
preparations, it is an effective antiplatelet treatment of choice for long
term treatment and prevention of certain forms of ischemic attacks.
In the treatment of acute myocardial infarction (heart attack), for
prevention of heart attack in certain high-risk group patients and for
prevention of stroke after transient ischemic attack (TIA).
Dosage and Administration
One capsule daily to be taken with a glass of water.
Severe hepatic and renal disease, haemophilia or other bleeding disorders,
erosive gastritis or peptic ulcers. Patients who are allergic to aspirin.
Side Effect(s) / Adverse Reaction(s)
The main adverse reactions associated with Aspirin therapy include
gastrointestinal distress, nausea, vomiting, erosion of the gastric mucosa,
ulceration and occult blood loss.
Precaution(s) / Warning(s)
1. Because of its relatively low dosage and enteric coating dosage form, the
risk of Casprin in causing GI ulceration is greatly reduced. However, care
should be taken in administering Casprin to patients with prior history of
serious GI events.
2. Concurrent use of Casprin with alcoholic beverages should be avoided in
order to avoid GI toxicity.
3. Care should be taken when Aspirin is administered to asthmatics patients.
4. Caution is necessary when renal or hepatic function is impaired.
5. The use of Aspirin in children under the age of 16 years is not
recommended because of the risk of Reye's syndrome.
6. Usage in Pregnancy:
Animals studies have shown that Aspirin can cause birth defects in numerous
species. There is no conclusive evidence that Aspirin causes malformation in
humans. Drug such as Aspirin inhibit prostaglandin synthesis. When given
late in pregnancy, it may cause premature closure of the fetal ductus
arteriosus, prolong labour and delay birth. Aspirin increases the bleeding
time both in the newborn infant and in the mother because of its
antiplatelet effects. Products containing Aspirin should be avoided in late
1. Concurrent administration of Aspirin and dipyridamole may result in an
increase in peak plasma-salicylate concentration and area under the curve.
2. Serum-salicylate concentrations may be reduced by concurrent
administration of corticosteroids.
3. Aspirin may enhance the activity of coumarin anticoagulant, sulphonylurea,
hypoglycaemic agent, methotrexate, phenytoin and valproic acid.
Symptoms and Treatment for Overdosage and Antidote(s)
Mild cases may produce nausea, vomiting, sweating, thirst and tachycardia.
Severe overdosage may show fever and CNS disturbances such as convulsions,
hallucinations, coma and respiratory failure. Management includes gastric
lavage and emesis for mild cases; in severe cases, barbiturate
administrations or dialysis may be required.
2 years from the date of manufacture.
Keep in a tight container. Store at temperature below 30°C. Protect from
light and moisture.
Product Description and Packing(s)
A size #4 orange transparent cap and colorless transparent body vegetable
capsule, containing white to off-white granules, and both cap and body are
impressed with "AECp".
Plastic container of 500's (for export only) .
Blister packing of 10's x 10, 10's x 3, 30's, 30's x 100 and 30's x 50.